Patents by Inventor Stephen M. Lynch
Stephen M. Lynch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11834447Abstract: The Invention provides indole derivatives of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1e, R1f, A, X, Y, Z, and W4 are defined as set forth in the specification. The Invention also provides the use of compounds of Formula I and the pharmaceutically acceptable salts and solvates thereof to treat pain. In certain embodiments, the Compounds of the Invention are effective in treating a disorder responsive to blockade of one or more sodium channels.Type: GrantFiled: July 30, 2020Date of Patent: December 5, 2023Assignee: Purdue Pharma L.P.Inventors: Stephen M. Lynch, Jiangchao Yao, Jae Hyun Park, Laykea Tafesse
-
Patent number: 11554086Abstract: The present disclosure relates to stable cosmetic compositions that include high levels of free glycolic acid. The cosmetic compositions typically include: glycolic acid and/or a salt thereof; at least one non-silicone fatty compound; at least one emulsifier; at least one water-soluble solvent; at least one silicone; and water. The cosmetic compositions are in the form of an emulsion, in particular, a water-in-oil emulsion, and typically have a low pH of below 7. Also, the cosmetic compositions have high amount of free glycolic acid, for example, at least 6 wt. % of free glycolic acid, based on the total weight of the cosmetic composition. The cosmetic compositions are particularly useful for improving the appearance of skin. Accordingly, the instant disclosure relates to methods of treating skin, for example, improving the appearance of skin using the cosmetic compositions.Type: GrantFiled: December 29, 2017Date of Patent: January 17, 2023Assignee: L'OREALInventors: Madeline Jane Sverdlove, Patricia Maribel Brieva, Maggie Helen Su, Stephen M. Lynch
-
Publication number: 20200361929Abstract: The Invention provides indole derivatives of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1e, R1f, A, X, Y, Z, and W4 are defined as set forth in the specification. The Invention also provides the use of compounds of Formula I and the pharmaceutically acceptable salts and solvates thereof to treat pain. In certain embodiments, the Compounds of the Invention are effective in treating a disorder responsive to blockade of one or more sodium channels.Type: ApplicationFiled: July 30, 2020Publication date: November 19, 2020Inventors: Stephen M. Lynch, Jiangchao Yao, Jae Hyun Park, Laykea Tafesse
-
Patent number: 10730866Abstract: The Invention provides indole derivatives of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1e, R1f, A, X, Y, Z, and W4 are defined as set forth in the specification. The Invention also provides the use of compounds of Formula I and the pharmaceutically acceptable salts and solvates thereof to treat pain. In certain embodiments, the Compounds of the Invention are effective in treating a disorder responsive to blockade of one or more sodium channels.Type: GrantFiled: April 7, 2015Date of Patent: August 4, 2020Assignee: Purdue Pharma L.P.Inventors: Stephen M. Lynch, Jiangchao Yao, Jae Hyun Park, Laykea Tafesse
-
Patent number: 10125113Abstract: The present disclosure provides dibenzazepine derivatives having Formula I or I(A): and the pharmaceutically acceptable salts and solvates thereof, wherein R3a, R3b, R6, V1, V2, Z1, Z2, Z3, and G are defined as set forth in the specification. The present disclosure is also directed to the use of the compounds of Formula I or I(A), and the pharmaceutically acceptable salts or solvates thereof, to treat a disorder responsive to the blockade of one or more sodium channels. In one embodiment, the compounds of the present disclosure are useful for treating pain.Type: GrantFiled: June 14, 2017Date of Patent: November 13, 2018Assignee: Purdue Pharma L.P.Inventors: Stephen M. Lynch, Laykea Tafesse
-
Patent number: 10047075Abstract: The present disclosure provides pyridines and pyrimidines of Formula I and pharmaceutically acceptable salts and solvates thereof: wherein A, G, W1, W2, W3, and R5 are defined as set forth in the specification. The present disclosure also provides uses of the compounds of Formula I and pharmaceutically acceptable salts and solvates thereof. In certain embodiments, Compounds of the present disclosure are useful for treating pain. In another embodiment, Compounds of the present disclosure are useful for treating a disorder responsive to blockade of sodium channels, or alleviating symptoms of the disorder.Type: GrantFiled: January 23, 2015Date of Patent: August 14, 2018Assignee: Purdue Pharma L.P.Inventor: Stephen M. Lynch
-
Publication number: 20170283392Abstract: The present disclosure provides dibenzazepine derivatives having Formula I or I(A): and the pharmaceutically acceptable salts and solvates thereof, wherein R3a, R3b, R6, V1, V2, Z1, Z2, Z3, and G are defined as set forth in the specification. The present disclosure is also directed to the use of the compounds of Formula I or I(A), and the pharmaceutically acceptable salts or solvates thereof, to treat a disorder responsive to the blockade of one or more sodium channels. In one embodiment, the compounds of the present disclosure are useful for treating pain.Type: ApplicationFiled: June 14, 2017Publication date: October 5, 2017Inventors: Stephen M. Lynch, Laykea Tafesse
-
Patent number: 9695144Abstract: The present disclosure provides dibenzazepine derivatives having Formula I or I(A): and the pharmaceutically acceptable salts and solvates thereof, wherein R3a, R3b, R6, V1, V2, Z1, Z2, Z3, and G are defined as set forth in the specification. The present disclosure is also directed to the use of the compounds of Formula I or I(A), and the pharmaceutically acceptable salts or solvates thereof, to treat a disorder responsive to the blockade of one or more sodium channels. In one embodiment, the compounds of the present disclosure are useful for treating pain.Type: GrantFiled: November 25, 2014Date of Patent: July 4, 2017Assignee: Purdue Pharma L.P.Inventors: Stephen M. Lynch, Laykea Tafesse
-
Publication number: 20170008882Abstract: The present disclosure provides pyridines and pyrimidines of Formula I and pharmaceutically acceptable salts and solvates thereof: wherein A, G, W1, W2, W3, and R5 are defined as set forth in the specification. The present disclosure also provides uses of the compounds of Formula I and pharmaceutically acceptable salts and solvates thereof. In certain embodiments, Compounds of the present disclosure are useful for treating pain. In another embodiment, Compounds of the present disclosure are useful for treating a disorder responsive to blockade of sodium channels, or alleviating symptoms of the disorder.Type: ApplicationFiled: January 23, 2015Publication date: January 12, 2017Inventor: Stephen M. Lynch
-
Patent number: 9464098Abstract: The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are LMP7 inhibitors and may be useful in treating associated inflammatory diseases and disorders such as, for example, rheumatoid arthritis, lupus and irritable bowel disease.Type: GrantFiled: November 29, 2013Date of Patent: October 11, 2016Assignee: HOFFMANN-LA ROCHE INC.Inventors: Stephen M. Lynch, Werner Neidhart, Jean-Marc Plancher, Tanja Schulz-Gasch
-
Publication number: 20150329565Abstract: The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are LMP7 inhibitors and may be useful in treating associated inflammatory diseases and disorders such as, for example, rheumatoid arthritis, lupus and irritable bowel disease.Type: ApplicationFiled: November 29, 2013Publication date: November 19, 2015Inventors: Stephen M. Lynch, Werner Neidhart, Jean-Marc Plancher, Tanja Schulz-Gasch
-
Publication number: 20150299143Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are LMP7 inhibitors and may be useful in treating associated inflammatory diseases and disorders such as, for example, rheumatoid arthritis, lupus and irritable bowel disease.Type: ApplicationFiled: November 29, 2013Publication date: October 22, 2015Applicant: F. HOFFMANN-LA ROCHE AGInventors: Stephen M. Lynch, Rainer E. Martin, Werner Neidhart, Jean-Marc Plancher, Tanja Schulz-Gasch
-
Publication number: 20150284383Abstract: The Invention provides indole derivatives of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1e, R1f, A, X, Y, Z, and W4 are defined as set forth in the specification. The Invention also provides the use of compounds of Formula I and the pharmaceutically acceptable salts and solvates thereof to treat pain. In certain embodiments, the Compounds of the Invention are effective in treating a disorder responsive to blockade of one or more sodium channels.Type: ApplicationFiled: April 7, 2015Publication date: October 8, 2015Inventors: Stephen M. Lynch, Jiangchao Yao, Jae Hyun Park, Laykea Tafesse
-
Publication number: 20150274777Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein X, R1, R1?, R2, R2?, R3, R4, R4? and R5 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are LMP7 inhibitors and may be useful in treating associated inflammatory diseases and disorders such as, for example, rheumatoid arthritis, lupus and irritable bowel disease.Type: ApplicationFiled: September 30, 2013Publication date: October 1, 2015Inventors: Stephen M. Lynch, Arjun Narayanan, Sandra Steiner
-
Publication number: 20150266920Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1, R2, R3 and R3? are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are LMP7 inhibitors and may be useful in treating associated inflammatory diseases and disorders such as, for example, rheumatoid arthritis, lupus and irritable bowel disease.Type: ApplicationFiled: October 9, 2013Publication date: September 24, 2015Inventors: Stephen M. Lynch, Arjun Narayanan
-
Publication number: 20150175569Abstract: The present disclosure provides dibenzazepine derivatives having Formula I or I(A): and the pharmaceutically acceptable salts and solvates thereof, wherein R3a, R3b, R6, V1, V2, Z1, Z2, Z3, and G are defined as set forth in the specification. The present disclosure is also directed to the use of the compounds of Formula I or I(A), and the pharmaceutically acceptable salts or solvates thereof, to treat a disorder responsive to the blockade of one or more sodium channels. In one embodiment, the compounds of the present disclosure are useful for treating pain.Type: ApplicationFiled: November 25, 2014Publication date: June 25, 2015Inventors: Stephen M. Lynch, Laykea Tafesse
-
Patent number: 8658646Abstract: The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.Type: GrantFiled: August 31, 2012Date of Patent: February 25, 2014Assignee: Hoffmann-LaRoche Inc.Inventors: Shaoqing Chen, Javier de Vicente Fidalgo, Matthew Michael Hamilton, Johannes Cornelius Hermann, Joshua Kennedy-Smith, Hongju Li, Allen John Lovey, Matthew C. Lucas, Kin-Chun Thomas Luk, Stephen M. Lynch, Counde O'yang, Fernando Padilla, Ryan Craig Schoenfeld, Achyutharao Sidduri, Michael Soth, Ce Wang, Peter Michael Wovkulich, Xiaohu Zhang
-
Patent number: 8518945Abstract: The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables n, p, q, Q, X, X? and Y are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.Type: GrantFiled: March 4, 2011Date of Patent: August 27, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Robert Than Hendricks, Johannes Hermann, Rama Kondru, Yan Lou, Stephen M. Lynch, Timothy D. Owens, Michael Soth
-
Patent number: 8513425Abstract: Compounds of the formula: or pharmaceutically acceptable salts thereof, wherein m, n, Ar, R1, R2, Ra and Rb are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.Type: GrantFiled: November 21, 2011Date of Patent: August 20, 2013Assignee: Roche Palo Alto LLCInventors: Pravin Iyer, Clara Jeou Jen Lin, Stephen M. Lynch, Matthew C. Lucas, Ann Marie Madera, Kerem Erol Ozboya, Robert James Weikert, Ryan Craig Schoenfeld
-
Patent number: 8481541Abstract: The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q, R2, R3, and Y are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.Type: GrantFiled: March 3, 2011Date of Patent: July 9, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Robert Than Hendricks, Johannes Hermann, Rama Kondru, Yan Lou, Stephen M. Lynch, Timothy D. Owens, Michael Soth